Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GRN | P28799 | 1/20 | 0.40 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27787704 | 0.84 | BAZ2B (0.66) | BAZ2BKDM4EGAARAB9AKMT2A | |
| SCHEMBL357627 | 0.83 | BAZ2B (0.63) | BAZ2BKDM4EGAARAB9AKMT2A | |
| SCHEMBL1080282 | 0.81 | BAZ2B (0.61) | BAZ2BKDM4EGAARAB9AKMT2A | |
| SCHEMBL1555279 | 0.81 | BAZ2B (0.61) | BAZ2BKDM4EGAARAB9AKMT2A | |
| SCHEMBL193910 | 0.81 | BAZ2B (0.61) | BAZ2BKDM4EGAARAB9AKMT2A | |
| SCHEMBL6994851 | 0.80 | BAZ2B (0.71) | BAZ2BKDM4EGAARAB9AKMT2A | |
| SCHEMBL15964702 | 0.80 | BAZ2B (0.44) | BAZ2B | |
| SCHEMBL12740599 | 0.79 | HCAR2 (0.43) | BAZ2BKDM4EGAARAB9AKMT2A | |
| Hydrochloric Acid SCHEMBL3491832 | 0.79 | BAZ2B (0.59) | BAZ2BKDM4EGAARAB9AKMT2A | |
| SCHEMBL19143370 | 0.78 | BAZ2B (0.53) | BAZ2BKDM4EGAARAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 720 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110167944-B | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-08-23 | — | — | CN | claimed |
| CN-111108109-A | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | 利奥制药有限公司 | 2020-05-05 | — | — | CN | claimed |
| CN-110099905-A | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | 利奥制药有限公司 | 2019-08-06 | — | — | CN | claimed |
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-03-07 | — | — | US | claimed |
| EP-1680124-B1 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | PFIZER PROD INC (US) | 2017-05-31 | — | — | EP | claimed |
| US-9328107-B2 | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | claimed |
| US-20150322054-A1 | 1,3-Oxazines As Bace1 And/Or Bace2 Inhibitors | HOFFMANN-LA ROCHE INC. | 2015-11-12 | — | — | US | claimed |
| EP-2635567-B1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2015-10-28 | — | — | EP | claimed |
| US-9115098-B2 | 1,3-oxazines as BACE1 and/or BACE2 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2015-08-25 | — | — | US | claimed |
| EP-2018371-B1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2015-03-04 | — | — | EP | claimed |
| US-20050113548-A1 | Solid powder coating crosslinker | BAYER MATERIALSCIENCE LLC | 2005-05-26 | — | — | US | claimed |
| US-6894138-B1 | Blocked polyisocyanate | BAYER MATERIALSCIENCE LLC (US) | 2005-05-17 | — | — | US | claimed |
| US-20050096375-A1 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | PFIZER INC. | 2005-05-05 | — | — | US | claimed |
| US-6869953-B2 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMAN-LA ROCHE INC. (US) | 2005-03-22 | — | — | US | claimed |
| US-20050031903-A1 | Iridium compound and organic electroluminescent device using the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2005-02-10 | — | — | US | claimed |
| US-20040192744-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HAAG RAINER (DE) | 2004-09-30 | — | — | US | claimed |
| EP-1299356-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-02-11 | — | — | EP | claimed |
| CN-1447794-A | Novel compounds | ASTRAZENECA AB (SE) | 2003-10-08 | — | — | CN | claimed |
| US-20030153555-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-08-14 | — | — | US | claimed |
| US-20030139404-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2003-07-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192744-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | NAT1, CYP1A1, UGT1A1 | BAZ2B 3691/4885KDM4E 2857/4885GAA 612/4885 |
| US-20030153555-A1 | Novel compounds | RPS4Y1, RPS4X, UGT2B7 | BAZ2B 3376/4885KDM4E 1665/4885GAA 1042/4885 |
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR1A | BAZ2B 3789/4885KDM4E 2520/4885GAA 1403/4885 |
| US-20050031903-A1 | Iridium compound and organic electroluminescent device using the same | IK, ALPL, PPIP5K2 | BAZ2B 2188/4885KDM4E 1192/4885GAA 2510/4885 |
| US-20050096375-A1 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | SLC6A5, SLC1A5, SLC6A3 | BAZ2B 3037/4885KDM4E 2032/4885GAA 1239/4885 |
| US-20030139404-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | NAT1, CYP1A1, UGT1A1 | BAZ2B 3691/4885KDM4E 2857/4885GAA 612/4885 |
| US-20150322054-A1 | 1,3-Oxazines As Bace1 And/Or Bace2 Inhibitors | BACE2, BACE1, PSEN1 | BAZ2B 421/4885KDM4E 2102/4885GAA 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.